Home LiteratureArticle Details
PMID: 22158902 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b.

Kobashigawa Y, Tomitaka A, Kumeta H, Noda NN, Yamaguchi M, Inagaki F

Abstract

Cbl-b is a RING-type E3 ubiquitin ligase that functions as a negative regulator of T-cell activation and growth factor receptor and nonreceptor-type tyrosine kinase signaling. Cbl-b dysfunction is related to autoimmune diseases and cancers in humans. However, the molecular mechanism regulating its E3 activity is largely unknown. NMR and small-angle X-ray scattering analyses revealed that the unphosphorylated N-terminal region of Cbl-b forms a compact structure by an intramolecular interaction, which masks the interaction surface of the RING domain with an E2 ubiquitin-conjugating enzyme. Phosphorylation of Y363, located in the helix-linker region between the tyrosine kinase binding and the RING domains, disrupts the interdomain interaction to expose the E2 binding surface of the RING domain. Structural analysis revealed that the phosphorylated helix-RING region forms a compact structure in solution. Moreover, the phosphate group of pY363 is located in the vicinity of the interaction surface with UbcH5B to increase affinity by reducing their electrostatic repulsion. Thus, the phosphorylation of Y363 regulates the E3 activity of Cbl-b by two mechanisms: one is to remove the masking of the RING domain from the tyrosine kinase binding domain and the other is to form a surface to enhance binding affinity to E2.

MeSH Terms
Autoimmune Diseases/metabolism Escherichia coli/metabolism Gene Expression Regulation, Neoplastic Humans Magnetic Resonance Spectroscopy/methods Models, Molecular Molecular Conformation Neoplasms/metabolism Phosphorylation Protein Conformation Protein Structure, Tertiary Proto-Oncogene Proteins c-cbl/chemistry,physiology Scattering, Radiation Ubiquitin-Protein Ligases/chemistry X-Rays
Chemicals
Proto-Oncogene Proteins c-cbl Ubiquitin-Protein Ligases
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Kobashigawa Yoshihiro
Department of Structural Biology, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University, Sapporo, Hokkaido 001-0021, Japan.
Tomitaka Akira
Kumeta Hiroyuki
Noda Nobuo N
Yamaguchi Masaya
Inagaki Fuyuhiko
References (32)
32 references, click to expand
  1. E2 interaction and dimerization in the crystal structure of TRAF6.
    Nat Struct Mol Biol. 2009 Jun;16(6):658-66 PMID: 19465916
  2. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.
    Cell Death Differ. 2008 May;15(5):841-8 PMID: 18219319
  3. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
    Nature. 2009 Aug 13;460(7257):904-8 PMID: 19620960
  4. Structural model of the UbcH5B/CNOT4 complex revealed by combining NMR, mutagenesis, and docking approaches.
    Structure. 2004 Apr;12(4):633-44 PMID: 15062086
  5. Phosphoinositide-incorporated lipid-protein nanodiscs: A tool for studying protein-lipid interactions.
    Anal Biochem. 2011 Mar 1;410(1):77-83 PMID: 21094116
  6. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
    Nat Genet. 2010 Sep;42(9):794-800 PMID: 20694012
  7. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.
    Cancer Res. 2010 Jun 15;70(12):4789-94 PMID: 20501843
  8. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.
    Mol Cell. 1999 Dec;4(6):1029-40 PMID: 10635327
  9. Recognition of UbcH5c and the nucleosome by the Bmi1/Ring1b ubiquitin ligase complex.
    EMBO J. 2011 Jul 19;30(16):3285-97 PMID: 21772249
  10. Regulating the regulator: negative regulation of Cbl ubiquitin ligases.
    Trends Biochem Sci. 2006 Feb;31(2):79-88 PMID: 16406635
  11. The Cbl family proteins: ring leaders in regulation of cell signaling.
    J Cell Physiol. 2006 Oct;209(1):21-43 PMID: 16741904
  12. Attachment of an NMR-invisible solubility enhancement tag using a sortase-mediated protein ligation method.
    J Biomol NMR. 2009 Mar;43(3):145-50 PMID: 19140010
  13. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
    Proc Natl Acad Sci U S A. 2003 May 13;100(10):5646-51 PMID: 12732733
  14. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases.
    Cell. 2000 Aug 18;102(4):533-9 PMID: 10966114
  15. Cbl-b regulates the CD28 dependence of T-cell activation.
    Nature. 2000 Jan 13;403(6766):216-20 PMID: 10646609
  16. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation.
    Mol Cell. 2001 Feb;7(2):355-65 PMID: 11239464
  17. E2-c-Cbl recognition is necessary but not sufficient for ubiquitination activity.
    J Mol Biol. 2009 Jan 16;385(2):507-19 PMID: 18996392
  18. Sortase-mediated protein ligation: a new method for protein engineering.
    J Am Chem Soc. 2004 Mar 10;126(9):2670-1 PMID: 14995162
  19. Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies.
    Leukemia. 2010 Aug;24(8):1539-41 PMID: 20555362
  20. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase.
    Nature. 1999 Mar 4;398(6722):84-90 PMID: 10078535
  21. The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor.
    Genes Dev. 2011 Jun 15;25(12):1262-74 PMID: 21685362
  22. Identification and functional analysis of CBLB mutations in type 1 diabetes.
    Biochem Biophys Res Commun. 2008 Mar 28;368(1):37-42 PMID: 18201552
  23. An efficient method for protein phosphorylation using the artificially introduced of cognate-binding modules into kinases and substrates.
    J Biotechnol. 2007 Sep 30;131(4):458-65 PMID: 17875337
  24. Identification of a ubiquitin-protein ligase subunit within the CCR4-NOT transcription repressor complex.
    EMBO J. 2002 Feb 1;21(3):355-64 PMID: 11823428
  25. Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment.
    J Biol Chem. 2008 Nov 14;283(46):31633-40 PMID: 18784070
  26. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations.
    J Biol Chem. 2004 Jul 2;279(27):28017-27 PMID: 15117950
  27. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis.
    Nat Genet. 2010 Jun;42(6):495-7 PMID: 20453840
  28. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.
    Nature. 2000 Jan 13;403(6766):211-6 PMID: 10646608
  29. Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene.
    Oncogene. 1995 Jun 15;10(12):2367-77 PMID: 7784085
  30. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
    J Biol Chem. 2010 Oct 15;285(42):32596-605 PMID: 20622007
  31. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information.
    J Am Chem Soc. 2003 Feb 19;125(7):1731-7 PMID: 12580598
  32. E3 ubiquitin ligases as T cell anergy factors.
    Nat Immunol. 2004 Sep;5(9):883-90 PMID: 15334084
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
1091-6490
Published
2011-12-20
Epub
2011-00-07
Pages
20579-84
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC3251137
Subset
IM
Databases
PDB
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com